ASH-话题@MedSci

#ASH#

242篇内容 | 2143人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1301298, encodeId=7be613012987a, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=J hepatology：Emricasan在治疗非酒精性脂肪性肝炎（NASH）肝硬化合并门脉高压中患者中的疗效, objectType=article, longId=185405, objectId=309b18540526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=309b18540526, replyNumber=0, likeNumber=88, createdTime=2019-12-31, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=309b18540526, moduleTitle=J hepatology：Emricasan在治疗非酒精性脂肪性肝炎（NASH）肝硬化合并门脉高压中患者中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=309b18540526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301297, encodeId=ad4d130129e60, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=2019 ASH -- 陆佩华院长分享CAR-T细胞免疫治疗新成果, objectType=article, longId=184995, objectId=1b4d18499539, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b4d18499539, replyNumber=0, likeNumber=77, createdTime=2019-12-22, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b4d18499539, moduleTitle=2019 ASH -- 陆佩华院长分享CAR-T细胞免疫治疗新成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b4d18499539)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301296, encodeId=7a94130129631, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=2019 ASH：阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期, objectType=article, longId=184850, objectId=079b184850dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=079b184850dc, replyNumber=0, likeNumber=105, createdTime=2019-12-18, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=079b184850dc, moduleTitle=2019 ASH：阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=079b184850dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301295, encodeId=550b1301295c4, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=CAR-T细胞疗法在美国血液学会ASH上大放异彩, objectType=article, longId=184849, objectId=fa79184849b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa79184849b1, replyNumber=0, likeNumber=61, createdTime=2019-12-18, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa79184849b1, moduleTitle=CAR-T细胞疗法在美国血液学会ASH上大放异彩, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa79184849b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301294, encodeId=c220130129407, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=亚盛医药抗耐药白血病新药HQP1351临床进展再获ASH年会口头报告，并荣膺“更佳研究”提名, objectType=article, longId=184648, objectId=db8b184648d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db8b184648d7, replyNumber=0, likeNumber=83, createdTime=2019-12-14, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db8b184648d7, moduleTitle=亚盛医药抗耐药白血病新药HQP1351临床进展再获ASH年会口头报告，并荣膺“更佳研究”提名, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db8b184648d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301293, encodeId=def2130129328, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=ASH19：Valemetostat治疗成人T细胞白血病的II临床试验, objectType=article, longId=184570, objectId=9bbd1845e0bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bbd1845e0bb, replyNumber=0, likeNumber=59, createdTime=2019-12-13, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bbd1845e0bb, moduleTitle=ASH19：Valemetostat治疗成人T细胞白血病的II临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bbd1845e0bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301292, encodeId=05a3130129297, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=ASH19：C1s抑制剂sutimlimab增加原发性冷凝集素疾病患者的血红蛋白水平, objectType=article, longId=184566, objectId=f8621845665a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8621845665a, replyNumber=0, likeNumber=31, createdTime=2019-12-13, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8621845665a, moduleTitle=ASH19：C1s抑制剂sutimlimab增加原发性冷凝集素疾病患者的血红蛋白水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8621845665a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301291, encodeId=54851301291c3, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=ASH19：CC-486可显著提高AML患者的总生存率, objectType=article, longId=184564, objectId=3ba01845641d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ba01845641d, replyNumber=0, likeNumber=84, createdTime=2019-12-13, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ba01845641d, moduleTitle=ASH19：CC-486可显著提高AML患者的总生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ba01845641d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301290, encodeId=076d1301290e5, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=2019 ASH指南：镰状细胞病——心肺和肾脏疾病, objectType=article, longId=184513, objectId=f6121845130a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6121845130a, replyNumber=0, likeNumber=32, createdTime=2019-12-11, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6121845130a, moduleTitle=2019 ASH指南：镰状细胞病——心肺和肾脏疾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6121845130a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301289, encodeId=ec9713012893f, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=2019 ASH指南：免疫性血小板减少症, objectType=article, longId=184512, objectId=e27518451236, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e27518451236, replyNumber=0, likeNumber=29, createdTime=2019-12-11, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e27518451236, moduleTitle=2019 ASH指南：免疫性血小板减少症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e27518451236)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301288, encodeId=c5ca130128882, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=ASH2019：外周血白血病负荷对难治/复发急性B淋巴细胞白血病CD19-CART细胞培养及临床疗效的影响, objectType=article, longId=184476, objectId=09e41844e696, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09e41844e696, replyNumber=0, likeNumber=31, createdTime=2019-12-11, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09e41844e696, moduleTitle=ASH2019：外周血白血病负荷对难治/复发急性B淋巴细胞白血病CD19-CART细胞培养及临床疗效的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09e41844e696)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301287, encodeId=95ea130128ea3, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=AASLD年会：新科技！新型机器学习模型可有效预测非酒精性脂肪性肝炎（NASH）发生, objectType=article, longId=183523, objectId=1d061835231a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d061835231a, replyNumber=0, likeNumber=75, createdTime=2019-11-25, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d061835231a, moduleTitle=AASLD年会：新科技！新型机器学习模型可有效预测非酒精性脂肪性肝炎（NASH）发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d061835231a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301286, encodeId=dec6130128697, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2019ASH抢先看】ELEVATE-TN研究：Acalabrutinib方案明显改善未经治CLL无进展生存, objectType=article, longId=182778, objectId=73dd182e78d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73dd182e78d9, replyNumber=0, likeNumber=81, createdTime=2019-11-11, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73dd182e78d9, moduleTitle=【2019ASH抢先看】ELEVATE-TN研究：Acalabrutinib方案明显改善未经治CLL无进展生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73dd182e78d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301285, encodeId=b4471301285e5, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2019ASH抢先看】R2-miniCHOP能否改善≥80岁DLBCL患者OS呢？答案可能在你意料之中, objectType=article, longId=182706, objectId=36ab182e0678, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36ab182e0678, replyNumber=0, likeNumber=112, createdTime=2019-11-10, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36ab182e0678, moduleTitle=【2019ASH抢先看】R2-miniCHOP能否改善≥80岁DLBCL患者OS呢？答案可能在你意料之中, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36ab182e0678)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301284, encodeId=909013012847f, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=第61届ASH：Kite将展示Yescarta治疗多种血液肿瘤的全新数据, objectType=article, longId=182556, objectId=c322182556d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c322182556d8, replyNumber=0, likeNumber=62, createdTime=2019-11-09, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c322182556d8, moduleTitle=第61届ASH：Kite将展示Yescarta治疗多种血液肿瘤的全新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c322182556d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301283, encodeId=eeb51301283e0, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=第61届ASH：bluebird bio将展示其基因和细胞疗法的全新数据, objectType=article, longId=182555, objectId=4dc11825558b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dc11825558b, replyNumber=0, likeNumber=54, createdTime=2019-11-09, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dc11825558b, moduleTitle=第61届ASH：bluebird bio将展示其基因和细胞疗法的全新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dc11825558b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301282, encodeId=a5b51301282c3, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=第61届ASH：Mustang Bio宣布MB-107和MB-106慢病毒基因疗法的全新数据, objectType=article, longId=182547, objectId=7fd018254ed0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fd018254ed0, replyNumber=0, likeNumber=74, createdTime=2019-11-08, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fd018254ed0, moduleTitle=第61届ASH：Mustang Bio宣布MB-107和MB-106慢病毒基因疗法的全新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fd018254ed0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301281, encodeId=160513012813d, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=Intercept向美国FDA提交奥贝胆酸治疗NASH的新药申请, objectType=article, longId=180297, objectId=fff018029e6c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fff018029e6c, replyNumber=0, likeNumber=82, createdTime=2019-10-01, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fff018029e6c, moduleTitle=Intercept向美国FDA提交奥贝胆酸治疗NASH的新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fff018029e6c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301280, encodeId=79a91301280ad, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=非酒精性脂肪性肝炎（NASH）的治疗：ASC40获得中国NMPA的IND, objectType=article, longId=178354, objectId=2b001e835408, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b001e835408, replyNumber=0, likeNumber=61, createdTime=2019-08-30, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b001e835408, moduleTitle=非酒精性脂肪性肝炎（NASH）的治疗：ASC40获得中国NMPA的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b001e835408)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301279, encodeId=315e13012e9a6, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=J Hepatol：全球流行病学调查：2型糖尿病患者中的NAFLD和NASH——系统评价和荟萃分析, objectType=article, longId=176270, objectId=2bed1e627012, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bed1e627012, replyNumber=0, likeNumber=75, createdTime=2019-07-28, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bed1e627012, moduleTitle=J Hepatol：全球流行病学调查：2型糖尿病患者中的NAFLD和NASH——系统评价和荟萃分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bed1e627012)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ASH

2020-05-29

kksonne (审核中...)

前往app查看评论内容

#ASH#

J hepatology：Emricasan在治疗非酒精性脂肪性肝炎（NASH）肝硬化合并门脉高压中患者中的疗效

2019-12-31

kksonne (审核中...)

前往app查看评论内容

#ASH#

2019 ASH -- 陆佩华院长分享CAR-T细胞免疫治疗新成果

2019-12-22

kksonne (审核中...)

前往app查看评论内容

#ASH#

2019 ASH：阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期

2019-12-18

kksonne (审核中...)

前往app查看评论内容

#ASH#

CAR-T细胞疗法在美国血液学会ASH上大放异彩

2019-12-18

kksonne (审核中...)

前往app查看评论内容

#ASH#

亚盛医药抗耐药白血病新药HQP1351临床进展再获ASH年会口头报告，并荣膺“更佳研究”提名

2019-12-14

kksonne (审核中...)

前往app查看评论内容

#ASH#

ASH19：Valemetostat治疗成人T细胞白血病的II临床试验

2019-12-13

kksonne (审核中...)

前往app查看评论内容

#ASH#

ASH19：C1s抑制剂sutimlimab增加原发性冷凝集素疾病患者的血红蛋白水平

2019-12-13

kksonne (审核中...)

前往app查看评论内容

#ASH#

ASH19：CC-486可显著提高AML患者的总生存率

2019-12-13

kksonne (审核中...)

前往app查看评论内容

#ASH#

2019 ASH指南：镰状细胞病——心肺和肾脏疾病

2019-12-11

kksonne (审核中...)

前往app查看评论内容

#ASH#

2019 ASH指南：免疫性血小板减少症

2019-12-11

kksonne (审核中...)

前往app查看评论内容

#ASH#

ASH2019：外周血白血病负荷对难治/复发急性B淋巴细胞白血病CD19-CART细胞培养及临床疗效的影响

2019-12-11

kksonne (审核中...)

前往app查看评论内容

#ASH#

AASLD年会：新科技！新型机器学习模型可有效预测非酒精性脂肪性肝炎（NASH）发生

2019-11-25

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2019ASH抢先看】ELEVATE-TN研究：Acalabrutinib方案明显改善未经治CLL无进展生存

2019-11-11

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2019ASH抢先看】R2-miniCHOP能否改善≥80岁DLBCL患者OS呢？答案可能在你意料之中

2019-11-10

kksonne (审核中...)

前往app查看评论内容

#ASH#

第61届ASH：Kite将展示Yescarta治疗多种血液肿瘤的全新数据

2019-11-09

kksonne (审核中...)

前往app查看评论内容

#ASH#

第61届ASH：bluebird bio将展示其基因和细胞疗法的全新数据

2019-11-09

kksonne (审核中...)

前往app查看评论内容

#ASH#

第61届ASH：Mustang Bio宣布MB-107和MB-106慢病毒基因疗法的全新数据

2019-11-08

kksonne (审核中...)

前往app查看评论内容

#ASH#

Intercept向美国FDA提交奥贝胆酸治疗NASH的新药申请

2019-10-01

kksonne (审核中...)

前往app查看评论内容

#ASH#

非酒精性脂肪性肝炎（NASH）的治疗：ASC40获得中国NMPA的IND

2019-08-30

kksonne (审核中...)

前往app查看评论内容

#ASH#

J Hepatol：全球流行病学调查：2型糖尿病患者中的NAFLD和NASH——系统评价和荟萃分析

2019-07-28

科室
- - 订阅+
  - 更多科室
工具
服务